Tandem Diabetes Care (TNDM) Current Deferred Revenue (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Current Deferred Revenue for 14 consecutive years, with $8.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue fell 19.84% year-over-year to $8.4 million; the trailing twelve-month figure through Jun 2026 stood at $8.4 million (down 19.84% YoY), and the FY2025 full-year result was $9.5 million, down 19.47% from the prior year.
• Current Deferred Revenue fell to $8.4 million in Q2 2026 per TNDM's latest filing, from $9.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $44.6 million in Q1 2024 and bottomed at $8.4 million in Q2 2026.
• Historically, Current Deferred Revenue has averaged $20.9 million across 5 years, with a median of $12.4 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue jumped 143.64% in 2023, then plunged 76.87% in 2025.
• Over 5 years, Current Deferred Revenue stood at $18.8 million in 2022, then soared by 133.55% to $44.0 million in 2023, then slumped by 73.11% to $11.8 million in 2024, then slipped by 19.47% to $9.5 million in 2025, then dropped by 11.51% to $8.4 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $8.4 million, $9.0 million, and $9.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.